- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00437450
Treatment of the Anemia of Myelodysplastic Syndromes by the Association of Epoetin Beta and All Trans Retinoic Acid
November 17, 2009 updated by: Groupe Francophone des Myelodysplasies
The purpose of this study is
- To evaluate the efficacy of association of Erythropoetin (Neorecormon) and ATRA in patients with low risk myelodysplastic syndromes
- To evaluate the tolerance of this treatment
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment
99
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Amiens, France, 84054
- CHU d'Amiens
-
Angers, France, 43033
- CHU d'Angers
-
Avignon, France, 84000
- CHU d'Avignon
-
Bayonne, France, 64100
- CH de la Cote Basque
-
Bobigny, France, 93009
- Hôpital Avicenne
-
Caen, France, 14033
- CHU de Caen
-
Clamart, France, 92140
- Hôpital Percy
-
Dijon, France, 21000
- CHU Dijon
-
Grenoble, France, 38043
- CHU Albert Michallon
-
Limoges, France, 87046
- CHRU Limoges
-
Lyon, France, 69437
- Chu Edouard Herriot
-
Marseille, France, 13009
- Institut Paoli Calmette
-
Nice, France, 06202
- CHU Archet
-
Paris, France, 75012
- Hôpital Saint Antoine
-
Paris, France, 75014
- Hopital Cochin
-
Paris, France, 75181
- Hôpital Hotel Dieu
-
Paris, France, 75010
- Hopital Necker
-
Quimper, France, 29107
- CH de Cournouaille
-
Reims, France, 51092
- CHU Robert Debré
-
Rouen, France, 76038
- Hopital Henri Becquerel
-
Strasbourg, France, 67098
- Hôpital Hautepierre
-
Toulouse, France, 31059
- CHU Purpan
-
Tours, France, 37044
- CHU Bretoneau
-
Vandoeuvre-les-Nancy, France, 54511
- CHU Brabois
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients ≥18 years with RA, RARS, RAEB (blasts <10%)
- Hb< 10g/dl > of 2 months or transfused since less 2 months
- Hb<12g/dl > of 2 months and thrombocytopenia defined by platelets < 50 000/mm3, or neutropenia<10 000mm3
- For women of child bearing age, necessity of contraception during all the duration of the study
Exclusion Criteria:
- Patient with lung disease, cardiac, neurological, gastro-intestinal or genito - urinary disorders not connected to genito -urinary not connected to myelodysplasia
- Patient having received intensive chemotherapy in the 3 months before inclusion in the protocol
- RAEBt
- RAEB >10% blasts
- Treatment with rHu-Epo, darbepoetin ou rHu-GCSF , 2 months before inclusion
- Patient presenting an iron , B12 vitamin or folic acid uncorrected deficit
- CMML
- Uncontrolled systemic hypertension
- creatinine clearance < 300 µM/L
- Pregnant patient or in period of lactation
- Life expectancy < 6 months
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
To evaluate the efficacy of association of Erythropoetin and ATRA in patients with low risk myelodysplastic syndromes
|
Secondary Outcome Measures
Outcome Measure |
---|
To evaluate the tolerance of this treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Lionel ADES, MD, Groupe Francophone des Myelodysplasies
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2004
Study Completion
September 1, 2005
Study Registration Dates
First Submitted
February 19, 2007
First Submitted That Met QC Criteria
February 19, 2007
First Posted (Estimate)
February 21, 2007
Study Record Updates
Last Update Posted (Estimate)
November 18, 2009
Last Update Submitted That Met QC Criteria
November 17, 2009
Last Verified
February 1, 2007
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 040759
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anemia in Myelodysplastic Syndromes
-
Sumitomo Pharma America, Inc.TerminatedAnemia in Myelodysplastic SyndromesUnited States
-
National Cancer Institute (NCI)CompletedChronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | de Novo Myelodysplastic Syndromes | Refractory Anemia | Refractory Anemia With Excess Blasts | Refractory Anemia With Excess Blasts in Transformation | Refractory Anemia With Ringed...United States
-
National Cancer Institute (NCI)CompletedChronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndromes | de Novo Myelodysplastic Syndromes | Refractory Anemia | Refractory Anemia With Excess Blasts | Refractory Cytopenia With Multilineage Dysplasia | Refractory Anemia With Excess Blasts in Transformation | Refractory Anemia...United States
-
National Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Childhood Myelodysplastic Syndromes | Previously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | de Novo Myelodysplastic Syndromes | Refractory Anemia | Refractory Anemia With Excess Blasts | Refractory Cytopenia With... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedChronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Previously Treated Myelodysplastic Syndromes | Refractory Anemia With Excess Blasts | Refractory Anemia With Excess Blasts in TransformationUnited States
-
Brian JonasPharmacyclics LLC.CompletedChronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Secondary Myelodysplastic Syndrome | de Novo Myelodysplastic Syndrome | Refractory Anemia With Excess Blasts in TransformationUnited States
-
Central Hospital, Nancy, FranceInserm U954 - N-GERE (Nutrition, Genetics and Exposition to Environmental...UnknownHigh-risk Myelodysplastic Syndromes With Excess BlastsFrance
-
Masonic Cancer Center, University of MinnesotaRecruitingMyelodysplastic Syndromes | Leukemia | Previously Treated Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Childhood Acute Myeloid Leukemia in Remission | Childhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Myeloid Leukemia | Secondary Myelodysplastic Syndrome and other conditionsUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedSevere Aplastic Anemia (SAA) | Myelodysplastic Syndrome (MDS) With Refractory Anemia (RA)United States
-
Case Comprehensive Cancer CenterCompletedMyelodysplastic Syndromes | Thrombocytopenia | Chronic Myelomonocytic Leukemia | de Novo Myelodysplastic Syndromes | Refractory Anemia | Refractory Anemia With Excess Blasts | Refractory Cytopenia With Multilineage Dysplasia | Refractory Anemia With Ringed SideroblastsUnited States
Clinical Trials on Epoetin/Atra
-
HighField Biopharmaceuticals CorporationTerminated
-
Amsterdam UMC, location VUmcUMC Utrecht; Erasmus Medical Center; University of Turin, Italy; Vejle HospitalCompleted
-
Associazione Italiana Ematologia Oncologia PediatricaUnknownAcute Promyelocytic LeukemiaItaly
-
MegalabsAzidus LaboratoriesNot yet recruitingAnemia of Chronic Kidney DiseaseUruguay
-
Hospital de Clinicas de Porto AlegreOswaldo Cruz Foundation; Rio Grande do Sul State Health Department - SES/RSCompletedComparison of the Efficacy of Two Formulations of Epoetin in Patients Undergoing Hemodialysis
-
M.D. Anderson Cancer CenterCompleted
-
Hoffmann-La RocheTerminated
-
General Hospital Sveti DuhCompletedEnd Stage Renal Disease | Renal Anemia | Regular Dialysis TreatmentCroatia
-
Hospira, now a wholly owned subsidiary of PfizerCompletedSolid Tumors | Lymphomas | Chemotherapy-induced Symptomatic Anemia | Malignant Hemopathies | MyelomasFrance